Drug Trial Radar · NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 25, 2021
Primary completion
Apr 15, 2027
Study completion Mar 12, 2029
Sponsor
- Lead sponsor
- Fred Hutchinson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- medac GmbH
- First posted
- Dec 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.
Conditions
- Acute Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Adult Diffuse Large Cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Burkitt Lymphoma
- Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Chronic Myelomonocytic Leukemia
- Hodgkin Lymphoma
- Lymphoblastic Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Mixed Phenotype Acute Leukemia
- Myelodysplastic Syndrome
- Prolymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Follicular Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Small Lymphocytic Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell TransplantationProcedure
Undergo allogeneic hematopoietic stem cell transplantation
CyclophosphamideDrug
Given IV
CyclosporineDrug
Given IV or PO
FilgrastimBiological
Given IV
FludarabineDrug
Given IV
Mycophenolate MofetilDrug
Given IV or PO
Mycophenolate SodiumDrug
Given PO
Total-Body IrradiationRadiation
Undergo total-body irradiation
TreosulfanDrug
Given IV
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Echocardiography TestProcedure
Undergo echocardiography
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT or PET/CT
Positron Emission TomographyProcedure
Undergo PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Graft failure/rejectionTime frame: Up to 2 years post-transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.